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广泛应用更加快了 HBsAg 突变株尤其是“a”表位突变株的出现。而传统的 HBsAg
诊断试剂主要采用针对“a”表位的特异性抗体，对突变毒株的检出能力有限，
加之部分突变株不能被现有疫苗保护，从而给临床诊断和血液安全带来巨大威胁。








成熟的 HBV 1.3 倍体基因组构建技术构建了 A、B、C、D、G 等多个基因型（涵




    以上述基础为支撑，本研究采用病毒与重组蛋白交叉免疫的方式，获得了近
300 株高亲和力的单克隆抗体，并对其进行了 LIA 初筛及全面的性质鉴定。在此
基础上，本研究通过进一步筛选挑选了 4 株单抗（WTS、6C10、42B6 和 15D1）
及羊抗-HBsAg-HRP，研制出了一种超敏广谱的 HBsAg 诊断试剂，建立了试剂盒
的生产工艺，并对其进行了大规模的性能评估。评估结果表明：本试剂对野生型
HBsAg 的分析灵敏度为 0.012IU/mL，高于做为对照的 5 种进口试剂 4-16 倍；对
















(95%CI: 99.57%~99.93%)。8 份 BBI 血清转换盘的结果显示本试剂对 HBV 早期
感染的检测性能在 BBI 公布的官方数据中仅次于 Prism。同时，本试剂对 22 份
从全国各地搜集的包括我国流行的各型 HBV 野生株及常见表面抗原突变株的血
清标本检测性能最佳。临床灵敏度方面，本试剂对 282 份 HBsAg 确认阳性（纸
条初筛阴性）的无症状携带者标本的检出率为 97.52% （95%CI: 94.95%~99.00%），
与 Hepanostika Ultra，Murex V3，Architect i2000SR 相当而显著优于 AxSYM V2






















China is a high-endemic area of HBV in which there are many AsCs with low 
viral load and newly infected persons in the window phase who are the main source of 
transfusion- transmitted HBV. Consequently, HBsAg assays with higher sensitivity 
need to be developed to overcome this problem. Meanwhile, such a vast number of 
infected individuals are reservoirs of HBV mutants. Moreover, under the influence of 
vaccination and antiviral therapy, HBsAg mutations, especially mutations within “a” 
determinant can emerge faster. Since traditional HBsAg assays were based on 
antibodies targeting “a” determinant and therefore had deficiencies in detecting 
mutants in this region. What‟s worse, part of these mutants could not be protected by 
currently used vaccines. So the deficiencies would cause clinically diagnostic escape 
and bring great threats to the blood safety. Fortunately, some newly developed HBsAg 
assays from Europe and USA can detect some of the HBsAg mutants. However, their 
capacities for detecting HBsAg mutants are far from satisfactory. Also, NAT is 
expensive and has complicated and troublesome procedures, which makes its use in 
clinic diagnosis and blood screening unsuitable. The purpose of this research is to 
develop a high-sensitive and broad-spectrum HBsAg assay which can detect all 
prevalent HBsAg mutants. Also, extensive evaluation work will be done. 
A molecular epidemiology survey has been conducted to identify prevalent 
HBsAg mutants in blood donors of Xiamen for two years. Also, extensive screening 
work has been done at some clinical units of Beijing, Wuhan, Guangzhou and Xian, in 
which dozens of samples of HBsAg mutations were collected. In these research, 
prevalent HBsAg mutations were summarized and underlying laws of mutation were 
inferred. Based on a well developed strategy for constructing 1.3 ploid omni-genetic 
HBV, the 1.3 ploid omni-genetic clones of HBV of many genotypes (such as genotype 
A, B, C, D , G and so on) and HBV strains including mutations in HBsAg region 
(such as G145R, C124Y, C138R, T140I, K141E and so on) were constructed and 
recombinant virions were obtained. Meanwhile, various recombinant native and 
mutant HBsAg proteins which included all prevalent mutations within the “a” 
determinant were obtained from the Baculovirus Expression System. These initial 
researches have laid a solid foundation for the development of the diagnotical kit. 
















mutant HBV were raised against these virions and proteins. Then, preliminary 
screening (based on linear immunoassay) and characterizing work were accomplished. 
On the basis of these research, 4 mAbs (WTS, 6C10, 42B6 and 15D1) were chose. 
Using these mAbs, together with a goat anti-HBsAg-HRP, a high-sensitive and 
broad-spectrum HBsAg assay was developed and then evaluated. Evaluation results 
indicate that its analytical sensitivity is 0.012 IU/mL for native HBsAg standard, 
which is 4 to 16 times higher than those of five imported assays. Analytical 
sensitivities for other 7 positive standards are less than 0.05IU/mL (3 of them belongs 
to3 serotypes and the remaining 4 are common HBsAg mutants); its speciality is 
99.81% (95%CI: 99.57%~99.93%). The results obtained with 8 seroconversion panels 
from BBI showed that this assay is second only to prism in all assays which tested 
these panels and published their data to BBI. The performance of the prototype assay 
is best in testing a sera panel comprising 22 samples which cover all prevalent HBV 
serotypes and genotypes in China and includes common HBsAg mutants. And the 
clinical sensitivity is 97.52% (275/282, 95%CI: 94.95%~99.00%) for 282 confirmed 
HBsAg positive samples (all samples tested negative by rapid test) collected from 
asymptomatic donors, which is comparable to Hepanostika Ultra，Murex V3，
Architect i2000SR and is significantly higher than AxSYM V2 and a homemade EIA. 
The results obtained with the instructing panel of NCCL further confirmed that the 
performance of this assay is greatly better than that of similar homemade assays. 
Finally, results of clinic trial conducted in 3 clinical units concluded that this assay is 
equivalent to Architect for clinical application. These results suggest that this assay is 
desirable for the prevention and threpy of HBV. 
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第一章 前 言 
乙型肝炎病毒（Hepatitis B Virus）感染已成为世界范围内共同而且重要的公
共卫生问题。临床以肝功能异常为主要特征并且伴多样性的临床表现。目前全世
界共有 20 亿人曾感染 HBV[1-2]，3.5~4 亿慢性 HBV 感染者，约占全球人口的 6%；
在全世界现有 HBV 感染者中 75%~80%在非洲，亚洲和西太平洋地区（图 1-1）。
慢性 HBV 携带者中有相当一部分发展成为 CHB，部分患者发展成为 HC，HCC
或非致癌性 HC 并发症(图 1-2)，每年因 HBV 感染而死亡的人数超过 110 万[3-5]。
卫生部 2006 年公布全国乙型肝炎病毒流行病学调查的结果：全国 1~59 岁人群乙
肝表面抗原携带率为 7.18%，比 1992 年的 9.75%降低了 26.36%。城市、农村人
群乙肝表面抗原携带率差异不显著，西部地区人群乙肝表面抗原携带率高于东部
地区。1~4 岁人群乙肝表面抗原携带率最低，为 0.96%；5~14 岁人群为 2.42％；
15~59 岁人群乙肝表面抗原携带率最高，达 8.57%（图 1-3）。 
 
图1-1 HBV感染的全球分布情况 










































HBV（Hepatitis B virus）属嗜肝 DNA 病毒科（hepadna viridae）不完全双链
DNA 病毒，其复制过程需经细胞内核糖核酸中间体（RNA intermediate）而与逆
转录相关，是一种逆转录病毒。（表 1-1） 
表 1-1 乙型肝炎病毒的病毒学特点[3] 
Table 1-1 Features of Hepatitis B virus 
分子病毒学特点 HBV(Dane particle) 
结构 42nm；具包膜；不完全 ds 基因组 
分类 嗜肝型脱氧核糖核酸病毒科 
感染受体 未知；一般认为 preS1,preS2,sAg 协同 
复制特点 通过 RNA 介导的逆转录复制方式 
变异速度 低（每年 1/10 万 base） 
基因分型 8 种亚型，8%种间差异 
是否整合入宿主基因组 是 
病毒动力学 2-3days 的半衰期，每天产生 10 亿到 100 亿个毒粒 
理化性质 强抵抗能力，30-32oC 至少存在 6months，-20oC 可存活
15years 
宿主范围 仅限于人，黑猩猩和恒河猴等高等灵长类动物 
分布特点 A 型：北欧和非洲；B 型和 C 型：东亚；D 型：中东，
北非，南欧；E 型：南非[6]；F 型：中南美洲[6-8]；G：法
国，北美[9]；H：拉丁美洲北部，中美洲，墨西哥[10]  
1.1 HBV 的颗粒结构 
1965 年，Blumberg 等[11]发现 “澳大利亚抗原”，1970 年 Dane 等[12]在电镜下
鉴定了HBV颗粒，又称Dane颗粒。Dane颗粒为双层壳的圆形颗粒，直径约 42nm，
分核心及外壳两部分，核心颗粒是直径约 27nm 的 20 面体。核心中含病毒基因
组、病毒编码的多聚酶等，其外是脂蛋白外膜。在一个典型的 HBV 感染者血液
中，HBV 可能存在以下三种颗粒结构：Dane 颗粒（具 LHBs，MHBs 和 SHBs，
core particle, HBV-DNA）; filamentous 颗粒（具 LHBs，MHBs 和 SHBs）；spherical





















Fig.1-4a: Electron micrograph (negative contrast) of hepatitis B virus particles 
(top), filamentous (bottom, right) and spherical (bottom, left) HBsAg particles. 
b: Model representation of the particle structure and the viral surface proteins 
(LHBs, MHBs, SHBs) with the S, PreS1 and PreS2 domains. Inside the virus 
particle can be found the core protein (HBc), the viral DNA and the virus-coded 
polymerase with reverse transcriptase (RT) and protein primer (PR) domains. 
 
1.2 HBV 的基因组结构 
HBV 是已知最小的真核细胞 DNA 病毒之一，基因组为一全长约 3.2kb
（3182~3221）的小环形 DNA。HBV DNA 双链长度不对称，单链部分占全长的
15~50%，全长的负链与病毒 mRNA 互补；正链仅 5‟末端固定，长度约 1700-2600nt。
HBV 颗粒核心内含有 DNA 聚合酶（DNAP/逆转录酶），以负链 DNA 为摸板，
将正链 DNA3‟末端延长而成为完全的 dsDNA。环状结构由负链和正链的附着末
端（约 224bp）维持，其两侧存在 11bp 正向重复序列（DR1 和 DR2）。此重复序
列与 HBV-DNA 的复制及与宿主 DNA 的整合相关。负链 DNA 从 DR1 内开始，
















末端形成末端重复。正链 DNA5‟末端有帽子结构（cap sequence）18bpRNA 以共
价键结合，而形成 DR2。正链 DNA3‟末端则结合 DNAP。 
HBV-DNA 共有 4 个 ORF，即：S ORF；P ORF；C ORF；X ORF[14-15]。四
种 ORF 分别有各自的启动子，S ORF 分别编码三个包膜蛋白：LHBs
（preS1+preS2+S）、MHBs (preS2+S)和 SHBs( S)。C ORF 分为 C 基因和前 C 区
（preC），各有起始密码 ATG，该段最为保守，是免疫攻击的 CTL 靶表位主要所
在，其变异易引起乙肝病毒的持续感染。P ORF 编码 HBV-DNA 聚合酶等，几乎
参与病毒复制的全过程。X 基因产物是一种重要的反式调节因子，具有转录激活
功能，其在病毒生命周期中的功能尚未充分阐明。HBx 蛋白可以激活细胞的原
癌基因和改变细胞的生长特性，可能与肝细胞癌的发生有关[16-18]。在 X 基因和 C
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